Sera Prognostics

Sera Prognostics, Inc. Class A Common Stock represents ownership in Sera Prognostics, a women’s health diagnostics company focused on improving maternal and neonatal care. The company develops and commercializes blood-based biomarker tests and predictive analytics designed to help physicians assess pregnancy-related risks, with its flagship PreTRM test used to estimate the risk of spontaneous preterm birth in singleton pregnancies. Sera Prognostics applies proteomics and bioinformatics to identify clinically useful markers from blood samples, supporting earlier risk awareness in prenatal care. Its product and service portfolio centers on pregnancy biomarker discovery, test validation, and diagnostic reporting for healthcare providers in the United States. Headquartered in Salt Lake City, Utah, and founded in 2008, Sera Prognostics operates as a specialized medical diagnostics business serving the broader women’s health and precision medicine markets.